Auro Laboratories Ltd vs Corona Remedies Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 04, 2026

Key Highlights

The Latest Trading Price of Auro Laboratories Ltd is ₹ 239.1 as of 30 Apr 15:30 . The P/E Ratio of Auro Laboratories Ltd is 0 as of March 2023 .The P/E Ratio of Corona Remedies Ltd is 0 as of March 2023 . The Market Cap of Auro Laboratories Ltd is ₹ 0 crore as of March 2023 .The Market Cap of Corona Remedies Ltd is ₹ 0 crore as of March 2023 . The revenue of Auro Laboratories Ltd for the Dec '25 is ₹ 0 crore as compare to the Mar '25 revenue of ₹ 0 crore. This represent the decline of 0% The revenue of Corona Remedies Ltd for the Dec '25 is ₹ 344.68 crore as compare to the Mar '25 revenue of ₹ 295.32 crore. This represent the growth of 16.71% The ebitda of Auro Laboratories Ltd for the Dec '25 is ₹ 0 crore as compare to the Mar '25 ebitda of ₹ 0 crore. This represent the decline of 0% The ebitda of Corona Remedies Ltd for the Dec '25 is ₹ 66.32 crore as compare to the Mar '25 ebitda of ₹ 55.85 crore. This represent the growth of 18.75% The net profit of Auro Laboratories Ltd changed from ₹ 0.75 crore to ₹ 0 crore over 7 quarters. This represents a CAGR of -100.00% The net profit of Corona Remedies Ltd changed from ₹ 29.95 crore to ₹ 41.27 crore over 7 quarters. This represents a CAGR of 20.11% The Dividend Payout of Auro Laboratories Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Dividend Payout of Corona Remedies Ltd changed from 20 % on March 2023 to 30 % on March 2025 . This represents a CAGR of 14.47% over 3 years .

About Auro Laboratories Ltd

Auro Laboratories Limited, founded in 1992, has been manufacturing and providing generic Active Pharmaceutical Ingredients (API).
Currently, the Company is specializing in producing Anti Diabetics like Metformin HCL. It is the first-line treatment for type 2 diabetes.
The Company is headquartered in Mumbai and it has manufacturing facility at Palghar in Maharashtra.
The facility has all the required certifications from Indian authorities and European registration organization Since inception, the Company focused on providing quality pharmaceuticals while maintaining high manufacturing standards.
Company presently has 1800 MTPA of Metformin HCL manufacturing capacity, with projects underway to expand the capacity to 3600 MTPA. The Company's primary focus was on Anti-Diabetic Drugs, which estimated to be one of the fastest growing therapeutic segments.

About Corona Remedies Ltd

Corona Remedies Limited was originally incorporated as CORONA Remedies Private Limited', a private limited company, dated August 27, 2004, issued by the Assistant Registrar of Companies, Gujarat at Dadra and Nagar Haveli.
Thereafter, Company converted into a public limited and Company name has changed to CORONA Remedies Limited'.
A fresh certificate of incorporation, is issued by the Registrar of Companies, Central Processing Centre, Manesar, Haryana on December 16, 2024. The manufacturing facilities of the Company are located at Solan (Himachal Pradesh) and at Bhayla (Ahmedabad, Gujarat).
The Company is engaged in manufacturing, trading and marketing of Pharmaceutical products in women's healthcare, cardio-diabeto, pain management, urology and other therapeutic areas. In 2004, Company launched the first division, and later named it as Pioneer' division in year 2010; launched Xemx (multispeciality) division in 2005.

FAQs for the comparison of Auro Laboratories Ltd and Corona Remedies Ltd

Which company has a larger market capitalization, Auro Laboratories Ltd or Corona Remedies Ltd?

Market cap of Auro Laboratories Ltd is 149 Cr while Market cap of Corona Remedies Ltd is 10,550 Cr

What are the key factors driving the stock performance of Auro Laboratories Ltd and Corona Remedies Ltd?

The stock performance of Auro Laboratories Ltd and Corona Remedies Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Auro Laboratories Ltd and Corona Remedies Ltd?

As of May 4, 2026, the Auro Laboratories Ltd stock price is INR ₹239.1. On the other hand, Corona Remedies Ltd stock price is INR ₹1725.0.

How do dividend payouts of Auro Laboratories Ltd and Corona Remedies Ltd compare?

To compare the dividend payouts of Auro Laboratories Ltd and Corona Remedies Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.